title: New pharmacological strategies in chronic heart failure.
abstract: Diuretics, ACE inhibitors and betablockers form the cornerstone of pharmacological treatment of chronic heart failure (CHF), while angiotensin receptor blockers are gaining ground. However, despite optimal treatment CHF remains a syndrome with poor prognosis. For this reason, a large number of new agents have been developed as add-on treatment over the last few years. Vasopeptidase inhibitors, moxonidine, endothelin antagonists, vasopressin antagonists, and selective aldosterone antagonists, are some of the new agents that were designed to interfere with different neurohormonal pathways. Immunomodulating agents, growth hormone, caspase inhibitors, adrenomedullin, and erythropoietin have different modes of action, which in general are less understood. Although most of the agents exhibited efficacy in preclinical trials, the clinical results have not always been similarly positive. The results of trials involving vasopeptidase inhibitors, endothelin antagonists, immunomodulating agents, and growth hormone have been disappointing. Other compounds like caspase inhibitors, adrenomedullin, and vasopressin antagonists are still at the early stages of development. Currently, the two most promising agents seem to be erythropoietin and the selective aldosterone receptor blocker eplerenone. In the present article an overview of new pharmacological developments for CHF is given, and the clinical value of these developments is discussed.
authors.affiliation: Department of Cardiology, St Antonius Hospital, Heart Lung Center Utrecht, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. r.wal@antonius.net
authors.forename: R M A
authors.initials: RM
authors.lastname: van de Wal
authors.forename: A A
authors.initials: AA
authors.lastname: Voors
authors.forename: H W M
authors.initials: HW
authors.lastname: Plokker
authors.forename: W H
authors.initials: WH
authors.lastname: van Gilst
authors.forename: D J
authors.initials: DJ
authors.lastname: van Veldhuisen
mesh_terms: D002317:Cardiovascular Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical / Q000639:trends*; D002908:Chronic Disease; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans
chemical_list: D002317:Cardiovascular Agents